Zarate C A, Tohen M, Banov M D, Weiss M K, Cole J O
Pharmacoepidemiology Center, McLean Hospital, Belmont, Mass 02178.
J Clin Psychiatry. 1995 Mar;56(3):108-12.
Clozapine has been increasingly shown to be effective in the acute and maintenance treatment of bipolar disorders. For this reason, we studied whether clozapine alone is effective as a mood stabilizer in patients with refractory bipolar disorders.
Subjects were part of a long-term follow-up study cohort of 193 patients with refractory mood disorders who were treated with clozapine at McLean Hospital prior to July 1, 1992. Patients included in this study were those older than 16 years with bipolar disorder (manic or mixed) and schizoaffective disorder, bipolar type, discharged taking clozapine alone (N = 17). Hospital records on all patients were reviewed by trained raters blind to "best-estimate" diagnoses. Response to clozapine was determined by the Clinical Global Impressions-Improvement (CGI-I) scale. Patients were contacted at least 6 months after clozapine initiation for semistructured follow-up interviews by raters blind to diagnosis and baseline information.
Seventeen subjects were contacted 16.1 +/- 5.6 months after clozapine initiation. Most of the 17 patients had previously failed trials of lithium, valproate, carbamazepine, neuroleptics, combinations of these, and electroconvulsive therapy; or had tardive dyskinesia. Of these patients, 65% (11/17) continued to be on clozapine therapy alone at follow-up and had no subsequent rehospitalization or affective episode. At follow-up, there was a significant decrease in the rehospitalization rate (p = .025) than before starting clozapine and a significant improvement in CGI-I scores (p = .02).
Clozapine monotherapy is an effective mood stabilizer, reducing both the number of affective episodes and rehospitalizations in patients with severe refractory bipolar illness.
越来越多的证据表明,氯氮平在双相情感障碍的急性治疗和维持治疗中均有效。因此,我们研究了单独使用氯氮平作为难治性双相情感障碍患者的心境稳定剂是否有效。
研究对象是193例难治性心境障碍患者长期随访研究队列的一部分,这些患者于1992年7月1日前在麦克莱恩医院接受氯氮平治疗。本研究纳入的患者为年龄大于16岁的双相情感障碍(躁狂或混合发作)及双相型分裂情感性障碍患者,出院时仅服用氯氮平(N = 17)。由对“最佳估计”诊断不知情的经过培训的评估者审查所有患者的医院记录。根据临床总体印象改善量表(CGI-I)确定对氯氮平的反应。在开始使用氯氮平至少6个月后,由对诊断和基线信息不知情的评估者对患者进行半结构式随访访谈。
在开始使用氯氮平16.1±5.6个月后联系到了17名受试者。这17名患者中的大多数之前使用锂盐、丙戊酸盐、卡马西平、抗精神病药物、这些药物的联合使用以及电休克治疗均失败;或患有迟发性运动障碍。在这些患者中,65%(11/17)在随访时继续仅接受氯氮平治疗,且随后未再住院或出现情感发作。随访时,再住院率较开始使用氯氮平前显著降低(p = 0.025),CGI-I评分显著改善(p = 0.02)。
氯氮平单药治疗是一种有效的心境稳定剂,可减少重度难治性双相情感障碍患者的情感发作次数和再住院次数。